Last reviewed · How we verify
Carvedilol SR 64mg, QD
Carvedilol SR is a non-selective beta-blocker with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.
Carvedilol SR is a non-selective beta-blocker with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload. Used for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction.
At a glance
| Generic name | Carvedilol SR 64mg, QD |
|---|---|
| Also known as | Dilatrend SR |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Beta-blocker with alpha-1 blocking activity |
| Target | Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Carvedilol blocks beta-1 and beta-2 adrenergic receptors as well as alpha-1 adrenergic receptors, resulting in decreased heart rate, reduced blood pressure, and improved cardiac efficiency. The sustained-release formulation allows once-daily dosing. It is commonly used in heart failure and hypertension management due to its vasodilatory and cardioprotective properties.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension
- Post-myocardial infarction
- Left ventricular dysfunction
Common side effects
- Dizziness
- Fatigue
- Hypotension
- Bradycardia
- Hyperglycemia
- Erectile dysfunction
Key clinical trials
- Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol SR 64mg, QD CI brief — competitive landscape report
- Carvedilol SR 64mg, QD updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI